Autologous Cell Therapy Market to Hit Valuation of US$ 44.55 Billion By 2033 | Astute Analytica
Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...
Pharmaceutical Technology on MSN2d
Sanofi’s Sarclisa combo approved in China for multiple myeloma
Sanofi has received China’s NMPA approval for the use of Sarclisa, combined with a standard-of-care regimen, for treating ...
GATC Health's Groundbreaking Stem Cell Therapy Could Revolutionize Diabetes Care
GATC Health Corp., a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, announces ...
Cure Today13h
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...
The Pharma Letter7d
Sarclisa wins MHRA nod for newly-diagnosed multiple myeloma
Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...
Adia Nutrition Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location
"With the global stem cell market expanding, we see an opportunity to make these treatments more accessible in the U.S.," ...
Metronomic chemotherapy: A promising approach for pediatric neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced ...
Adia Nutrition Advances Towards OTCQB Uplisting with Third-Party Audit and Provides Roadmap to Listing on Nasdaq Small Cap
Adia Nutrition's diverse portfolio, including its groundbreaking work in stem cell therapy through Adia Med, has positioned the company as a pioneer in the health sector. The anticipated uplisting is ...